XORTX Therapeutics Secures Funding for Advancement
XORTX Therapeutics Inc. (NASDAQ: XRTX), a forward-thinking clinical pharmaceutical company, has completed a successful private placement, raising a total of USD $114,500. This funding will significantly aid in the development of innovative therapies targeting gout and progressive kidney disease.
Details of the Private Placement Offering
In the recent Offering, XORTX issued 156,849 Units priced at USD $0.73 per Unit. Each Unit comprises a common share and a warrant, allowing investors to purchase additional common shares at USD $1.20 within a five-year period. Should the closing price of the common shares exceed USD $2.00 for ten consecutive trading days, an early expiry of these warrants will occur.
Utilization of Funds for Development Programs
The proceeds from this Offering are earmarked for the company’s research and development initiatives focused on treating gout and other critical kidney diseases. XORTX is committed to leveraging this funding to enhance its treatment protocols and improve the quality of life for individuals affected by these conditions.
Compliance and Regulatory Aspects
The private placement has received conditional approval from the TSX Venture Exchange. It is essential to note that the securities issued will be subject to a statutory hold period of four months and one day. The company emphasizes that the securities will not be registered under U.S. securities laws and cannot be offered or sold to U.S. persons unless registered or exempted.
A Closer Look at XORTX Therapeutics
XORTX is at the forefront of pharmaceutical advancements, with several lead product programs in development. These programs include XRx-026 aimed at gout treatment, as well as XRx-008 and XRx-101 addressing polycystic kidney disease and acute organ injury related to respiratory infections, respectively. An additional preclinical program, XRx-225, is in the pipeline targeting Type 2 diabetic nephropathy.
Commitment to Quality of Life Improvements
XORTX’s mission is clear: to develop therapies that target abnormal purine metabolism and inhibit uric acid production. Through this dedication, the company aims to significantly impact the health and well-being of those suffering from gout and other related diseases.
Company Contact Information
For more inquiries, stakeholders may reach out to:
Allen Davidoff, CEO
Email: adavidoff@xortx.com | Phone: +1 403 455 7727
Nick Rigopulos, Director of Communications
Email: nick@alpineequityadv.com | Phone: +1 617 901 0785
Frequently Asked Questions
What is the purpose of XORTX's recent funding?
The funding will support the development of innovative therapies for gout and kidney diseases.
How many units were issued in the private placement?
A total of 156,849 units were issued at a price of USD $0.73 per unit.
What are the key products in XORTX's pipeline?
XORTX is developing XRx-026 for gout, XRx-008 for polycystic kidney disease, and XRx-101 for acute organ injury.
What is the significance of the warrants in the Offering?
Warrants allow holders to purchase additional shares at USD $1.20, promoting long-term investment.
How can investors contact XORTX for more information?
Investors can reach out via the contact details provided for CEO Allen Davidoff and Director Nick Rigopulos.
